Company / Capital Returned to Shareholders
ImmunityBio, Inc. Capital Returned to Shareholders History
FY2016-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Returned to Shareholders
$2.5M
FY2021
5-year range
$2.5M / $2.5M
FY2017-FY2021
Trend
-
vs FY2020
Sector context
#45 of 52
Health Care
What the data says
ImmunityBio, Inc.'s capital returned to shareholders of $3M is lower than 87% of companies in the Health Care sector (FY2021). Capital Returned to Shareholders returned to growth in FY2021 after 2 years of decline, reaching $3M.
Based on SEC 10-K filings.
$3M in FY2021 with a 3-year CAGR of -46.0%.
Remained stable around $3M over the past 2 years.
Health Care sector context is included.
Capital Returned to Shareholders over time
Growth rates
- 3-Year CAGR
- -46.0%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 13% in Health CareTop 87% of 52This company $2.5M Sector average $1.3B
▼
-99.8% below sector average
Key checks
Key Insights
- 3-year CAGR of -46.0%, indicating a declining trend.
- Ranks #45 out of 52 companies in the Health Care sector.
- Peak capital returned to shareholders was recorded in FY2018.
- Lowest capital returned to shareholders in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score -7.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital Returned to ShareholdersValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | $2.5M | - |
| FY2020 | $0 | -100.0% |
| FY2019 | $2.5M | -84.2% |
| FY2018 | $15.8M | +230.3% |
| FY2017 | $4.8M | - |
| FY2016 | $0 | -100.0% |
As of FY2021 · SEC 10-K · Updated Jun 30, 2026